GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC.

GlaxoSmithKline Holdings (Americas) Inc. specializes in the manufacturing of pharmaceutical preparations and biological products for federal health security initiatives. Their core capabilities include the aseptic production, formulation, and quality-controlled scaling of antiviral therapeutics and biologics, with demonstrated experience in meeting stringent U.S. government standards for emergency stockpiling. The contractor possesses technical expertise in GMP-compliant manufacturing processes, cold chain logistics for biological agents, and regulatory alignment with FDA and CDC requirements for strategic national supply readiness. Their specialization lies in rapid-response production of non-diagnostic biologics and oral/inhaled pharmaceuticals, ensuring stability, potency, and batch consistency under high-volume, time-sensitive conditions. The contractor has delivered critical medical products exclusively to the Department of Health and Human Services, primarily supporting the Strategic National Stockpile through the procurement of antiviral medications and emergency biologics. Their relationship with HHS reflects a focused partnership in public health preparedness, where consistent supply of therapeutics for pandemic and biothreat scenarios is paramount. Work has centered on lifecycle management of stockpiled assets, from manufacturing to regulatory documentation, ensuring compliance with federal medical countermeasure protocols. Industry focus is narrowly aligned with NAICS 325412 (pharmaceutical preparation manufacturing) and 325414 (biological product manufacturing), indicating deep specialization in non-diagnostic therapeutics rather than diagnostics or over-the-counter drugs. The contractor operates within the federal medical countermeasure market, serving as a trusted manufacturer of high-priority, regulated biologics and antiviral formulations for national defense and public health infrastructure. The company’s structure and certifications are not disclosed in available records, and no geographic or small business certifications are indicated. Its government market positioning is defined by technical precision in regulated manufacturing rather than broad-scale service delivery, positioning it as a niche supplier for mission-critical pharmaceutical and biological outputs.